Supplemental Financial Data

9 Months Ended

Sep. 30, 2023

Supplemental Financial Data [Abstract]

Supplemental Financial Data

3. Supplemental Financial Data

Inventories

Our inventory consisted of the following (in thousands):

	September 30, 2023		December 31, 2022
Raw materials:
Raw materials - clinical	$	18,427	$	17,061
Raw materials - commercial		4,380		2,699
Total raw materials		22,807		19,760
Work in process		2,651		2,109
Finished goods		176		164
Total inventory	$	25,634	$	22,033

Accrued Liabilities

Our accrued liabilities consisted of the following (in thousands):

	September 30, 2023		December 31, 2022
Clinical development expenses	$	89,217	$	116,460
In-licensing expenses		7,560		7,945
Commercial expenses		8,575		3,498
Other miscellaneous expenses		13,616		12,198
Total accrued liabilities	$	118,968	$	140,101